COPD
-
The climate cost of inhalers: What prescribers should know
Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.
-
Study explores geographic disparities in tobacco dependence treatment among veterans with COPD
Study author Arianne K. Baldomero, MD, said that reducing geographic barriers will require multidisciplinary approaches and innovative, equitable health care solutions.
-
Case discussions to address complexities of mediastinal lymphadenopathy diagnosis
Sebastian Kurz, MD, PhD, FCCP, will chair a Wednesday afternoon panel session that will guide attendees through imaging findings, differential diagnoses, and clinical decision-making in mediastinal lymphadenopathy.
-
Presenters to share insights into new ventilation reimbursement criteria
Peter Gay, MD, FCCP, will chair a session about the implications of revised coverage guidelines for noninvasive positive pressure ventilation devices for patients with COPD.
-
Clinicians to examine opportunities to confront dyspnea in COPD
Muhammad A. Zafar, MD, MSc, will chair a session exploring how dyspnea—more than just shortness of breath and discomfort—can be part of a downward spiral accompanying COPD.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Persistent mucus plugs linked to faster lung function decline in COPD
Investigator Sofia Mettler, MD, MPH, said the findings may point to a potential intervenable pathology in obstructive airway disease.
-
Sessions to explore next generation of care in COPD
Presentations across dozens of sessions will provide clinicians with an unparalleled opportunity to refine their expertise and help patients manage this disease, said CHEST Airways Disorders Curriculum Group Chair Shahid Sheikh, MD, FCCP.
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
